Background A polypill that includes key medications associated with improved outcomes
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …

Background The feasibility of conducting a large-scale Polypill clinical trial in developing
countries remains unclear. More information is needed regarding the efficacy in reducing the …

Background A fixed-dose combination therapy (polypill strategy) has been proposed as an
approach to reduce the burden of cardiovascular disease, especially in low-income and …

Objective The aim of this study was to determine the effect of polypill-based care on the
achievement of 2016 European Society of Cardiology (ESC) guideline targets for blood …

Prior studies have reported improvements in population-level risk factor burden and
cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a …

The prevention of cardiovascular disease (CVD) by using a polypill has gained increasing
momentum as a strategy to contain progression of the disease. Since its initial conception …

Antihypertensive, lipid lowering, antidiabetic and antiplatelet treatments all substantially
reduce the risk of cardiovascular morbid and fatal events. In real life, however, effective …

Background A polypill comprising statins, multiple blood-pressure–lowering drugs, and
aspirin has been proposed to reduce the risk of cardiovascular disease. Methods Using a 2 …

Background Most individuals at high cardiovascular disease (CVD) risk worldwide do not
receive any or optimal preventive drugs. We aimed to determine whether fixed dose …

Objective To evaluate the public health and economic benefits of adherence to a fixed-dose
combination polypill for the secondary prevention of cardiovascular (CV) events in adults …